Regulator recommends Samsung BioLogics axe CEO over accounting controversy
The SFC ruled that Samsung BioLogics had intentionally violated accounting rules to inflate the price of its IPO.
Top Headlines
Global Industry News
-
FMD deadline 'not the end’ of serialization process
from in-PharmaTechnologist.com
-
Tekni-Plex enhances packaging capabilities with tenth acquisition
from in-PharmaTechnologist.com
-
TriNetX adds 190m patient claims to its Diamond Network
from Outsourcing-Pharma.com
-
Quotient expands Reading facility tripling GMP capacity
from Outsourcing-Pharma.com
Hot Topics
-
Insight: Gaining MAH status in Jordan’s biosimilar market
Biosimilars
-
US FDA warning: Illegally marketed stem cell therapy made in substandard lab
Cell & Gene Therapies
-
First-in-man study appears to ‘awaken’ dormant hair follicles, says biotech
Pipelines
-
‘Illegal and corrupt advantage’: Federal grand jury serves criminal theft charges to JHL Biotech
Biosimilars
